Original Investigation | Psychiatry
A Cognitive Biotype of Depression Linking Symptoms, Behavior Measures,
Neural Circuits, and Differential Treatment OutcomesAPrespecifiedSecondaryAnalysisofaRandomizedClinicalTrial
LauraM.Hack,MD,PhD;LeonardoTozzi,MD,PhD;SamanthaZenteno,BA;AlisaM.Olmsted,MD;RachelHilton,MSN;JennaJubeir,BS;MayureshS.Korgaonk ar,PhD;
AlanF.Schatzberg,MD;JeromeA.Yesavage,MD;RuthO’Hara,PhD;LeanneM.Williams,PhD
Abstract
IMPORTANCE Cognitivedeficitsindepressionhavebeenassociatedwithpoorfunctionalcapacity,
frontalneuralcircuitdysfunction,andworseresponsetoconventionalantidepressants.H owever,it
isnotknownwhethertheseimpairmentscombinetogethertoidentifyaspecificcognitivesubgroup(or“biotype”)ofindividualswithmajordepressivedisorder(MDD),andtheextenttowhichtheseimpairmentsmediateantidepressantoutcomes.
OBJECTIVE ToundertakeasystematictestofthevalidityofaproposedcognitivebiotypeofMDD
acrossneuralcircuit,symptom,socialoccupationalfunction,andtreatmentoutcomemodalities.
DESIGN, SETTING, AND PARTICIPANTS Thissecondaryanalysisofarandomizedclinicaltrial
implementeddata-drivenclusteringinfindingsfromtheInternationalStudytoPredictOptimizedTreatmentinDepression,apragmaticbiomarkertrialinwhichpatientswithMDDwererandomizedina1:1:1ratiotoantidepressanttreatmentwithescitalopram,sertraline,orvenlafaxineextended-releaseandassessedatbaselineand8weeksonmultimodaloutcomesbetweenDecember1,2008,andSeptember30,2013.Eligiblepatientsweremedication-freeoutpatientswithnonpsychoticMDDinatleastthemoderaterange,andwererecruitedfrom17clinicalandacademicpractices;asubsetofthesepatientsunderwentfunctionalmagneticresonanceimaging.ThisprespecifiedsecondaryanalysiswasperformedbetweenJune10,2022,andApril21,2023.
MAIN OUTCOMES AND MEASURES Pretreatmentandposttreatmentbehavioralmeasuresof
cognitiveperformanceacross9domains,depressionsymptomsassessedusing2standarddepressionscales,andpsychosocialfunctionassessedusingtheSocialandOccupationalFunctioningAssessmentScaleandWorldHealthOrganizationQualityofLifescalewereanalyzed.Neuralcircuitfunctionengagedduringacognitivecontroltaskwasmeasuredusingfunctionalmagneticresonanceimaging.
RESULTS Atotalof1008patients(571[56.6%]female;mean[SD]age,37.8[12.6]years)
participatedintheoveralltrialand96patientsparticipatedintheimagingsubstudy(45[46.7%]female;mean[SD]age,34.5[13.5]years).Clusteranalysisidentifiedwhatmaybereferredtoasacognitivebiotypeof27%ofdepressedpatientswithprominentbehavioralimpairmentinexecutivefunctionandresponseinhibitiondomainsofcognitivecontrol.Thisbiotypewascharacterizedbyaspecificprofileofpretreatmentdepressivesymptoms,worsepsychosocialfunctioning( d= −0.25;
95%CI,−0.39to−0.11; P< .001),andreducedactivationofthecognitivecontrolcircuit(right
dorsolateralprefrontalcortex: d= −0.78;95%CI,−1.28to−0.27; P=.003).Remissionwas
comparativelylowerinthecognitivebiotypepositivesubgroup(73of188[3 8.8%]vs250of524
[47.7%]; P= .04)andcognitiveimpairmentspersistedregardlessofsymptomchange,remainingat
(continued)Key Points
Question Howareobjectivecognitive
deficitsindepressionassociatedwithsymptoms,neuralcircuits,andtreatmentoutcomes?
Findings Inthissecondaryanalysisofa
randomizedclinicaltrialin1008patientswithmajordepression,27%exhibitedpretreatmentglobalcognitiveimpairmentandsignificantlydecreasedbrainresponsetoacognitivetaskaswellasworseresponsetostandardpharmacotherapy,definingwhatmaybecategorizedasacognitivebiotype.Changesincognitivesymptomsoverthecourseoftreatmentmediatedtheassociationbetweenpretreatmentcognitivestatusandimprovementinoverallsymptomsandpsychosocialfunctioning.
Meaning Theseresultssuggestthat
considerationoftreatmentstargetingcognitivedysfunctioninasubsetofpatientswithdepressioniswarrantedtoattainsymptomaticandpsychosocialimprovement.
+Supplemental content
Authoraffiliationsandarticleinformationare
listedattheendofthisarticle.
Open Access. ThisisanopenaccessarticledistributedunderthetermsoftheCC-BYLicense.
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 1/13
Downloaded from jamanetwork.com by guest on 07/17/2024
Abstract (continued)
least0.2standarddeviationsbelowthehealthymean.Theextentofsymptomandfunctionalchange
wasspecificallymediatedbychangeincognitionbutnotthereverse.
CONCLUSIONS AND RELEVANCE Ourfindingssuggestthepresenceofacognitivebiotypeof
depressionwithdistinctneuralcorrelates,andafunctionalclinicalprofilethatrespondspoorlytostandardantidepressantsandinsteadmaybenefitfromtherapiesspecificallytargetingcognitivedysfunction.
TRIAL REGISTRATION ClinicalTrials.govIdentifier: NCT00693849
JAMA Network Open. 2023;6(6):e2318411.
CorrectedonJuly12,2023.doi: 10.1001/jamanetworkopen.2023.18411
Introduction
Majordepressivedisorder(MDD)isaserious,oftenchronicconditionwithastaggeringburdenthat
disruptspsychosocial,interpersonal,andworkplacefunction.Cognitiveimpairmentisrecognizedasamajorcontributortobothpoorfunctionaloutcomesandlackofsymptomrelieffromantidepressanttreatments.
1Suchimpairmentencompassesdeficitsinexecutivecontrol,attention,
andworkingmemoryrelevanttotheresearchdomaincriteriacognitivesystem2andtotheMDD
Diagnostic and Statistical Manual of Mental Disorders (FifthEdition,textrevision)diagnosticcriterion
ofpoorconcentrationandindecisiveness.3Weundertookasystematicevaluationofwhatwe
describeasacognitivedyscontrolbiotypeofdepression,usingbehavioralmeasurestoidentifythebiotypeprevalence,clinicalratingstoassessitsassociationwithsymptomsandfunction,functionalneuroimagingtorevealneuralmechanisticunderpinnings,andarandomizedclinicaltrialtodeterminewhethercognitiveimpairmentisacausalmediatorofpooroutcomesfollowingantidepressanttreatment(ADT).
AgrowingpoolofstudiesdocumentcognitiveimpairmentinMDDacrosstheadultlifespanand
assesstreatmentsforit.
4-6Thesestudieslackaconsistentbatteryofcognitivemeasuresanddonot
stratifydepressedpatientsbasedontheextentofcognitiveimpairment,possiblyleadingtomixedtreatmentresultsonefficacy.Giventhis,welackdataspecifictothepatientswithMDDdistinguishedbymoderate-to-severecognitiveimpairment,whichmayformaspecificbiotypesubgroup.
1,7,8
OurpreviousworkhasshownthatpatientswithMDD,inyoungtomid-adulthood,are
distinguishedfromhealthypatientsbyagroupmeanreductionincognitiveperformance,whichpersistsdespiteADTs
9andisimplicatedinnonremission.10Wehavealsoobservedthatnonremission
ischaracterizedbyameanreductioninactivationofthedorsolateralprefrontalcortex(dLPFC),11a
brainregionessentialinthecognitivecontrolcircuit,andbyalterationsintheconnectivityofthiscircuit.
12Inthisstudy,wepursuedasystematic,multimodalcharacterizationofourpriorproposed
putativeclinicalbiotypeofdepressioncalledthecognitivedyscontrolbiotype13(hereafterreferredto
ascognitive biotype forbrevity).
Weusedamachinelearningmethodofclusteranalysistoidentifythecognitivebiotypewithin
thebroaderMDDdiagnosis.Ourprimaryresearchgoalwastovalidatethecognitivebiotypeofdepressionbyassessingwhetheritisdistinguishedbybaselinesymptomandfunctionprofiles,bybaselineneuraldysfunctionsinthecognitivecontrolcircuit,andbypoorerresponsetostandardantidepressants.Wealsosoughttodeterminewhetherlackofameliorationofcognitiveimpairmentmediatespoorersymptomandfunctionoutcomesduringthetreatmentperiod(butnotthereverse).JAMA Network Open | Psychiatry
CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 2/13
Downloaded from jamanetwork.com by guest on 07/17/2024
Methods
Overview and Patients
Datawerefrom1008adultswithMDDwhoparticipatedintheInternationalStudytoPredict
OptimizedTreatmentinDepression(iSPOT-D)14andwereenrolledbetweenDecember1,2008,and
September30,2013( Supplement1 ).Ofthese,96completedtheiSPOT-Dimagingsubstudyand
wereusedinthisanalysis.15Thestudyprotocolwasreviewedandreceivedinstitutionalreviewboard
approvalateachclinicalsite.Participantsprovidedwritteninformedconsent.ThisprespecifiedsecondaryanalysiswasperformedbetweenJune10,2022,andApril21,2023.Bothsamplesizeandpowercalculationswereestablishedinthefullsample.
14,15Thefullsamplewasusedforallanalyses
exceptthefunctionalandstructuralneuroimaginganalyses,forwhichtheimagingsubsamplewasused.ThisstudyfollowstheConsolidatedStandardsofReportingTrials( CONSORT )reporting
guidelineforrandomizedstudies(eFigure1andeMethodsin Supplement2 ).
Patientswereassessedoncognitivetesting,symptoms,functionalcapacity,andfunctional
neuroimagingatbaseline,randomizedina1:1:1ratioto1of3widelyprescribedantidepressants—escitalopram(336patients),sertraline(336patients),orvenlafaxine-XR
14(336patients)—andthen
reassessedonthesamemeasuresafter8weeksoftreatment.Ofthetotalsample,712patientscompletedtreatment.
Cognitive Testing
Cognitiveperformancewasassessedusingastandardized,computerizedtestbattery,IntegNeuro(BrainResource),whichhasestablishednormsacross9decadesofthehealthylifespan,
16test-retest
reliability,17constructvaliditywithrespecttotraditionalneuropsychologicalbatteriesandbrain
measures,18,19andutilityindistinguishingcognitiveimpairmentsinpsychiatricgroups.20-23
IntegNeuroassessed9cognitivedomains(andtests),includingsustainedattention(ContinuousPerformanceTest),cognitiveflexibility(Stroop),decisionspeed(ChoiceReactionTime),executivefunction(Maze),informationprocessingspeed(SwitchingofAttention),psychomotorresponsespeed(MotorTapping),responseinhibition(Go/No-Go),verbalmemory(VerbalLearningandMemory),andworkingmemory(DigitSpan).Performancewasexpressedasastandarddeviationscorereferencedtoahealthynormmeanofzeroforeachtestandquantifiedbyaccuracy,reactiontime,and/orcompletiontime.Compositescoreswereobtainedbyaveragingperformanceoneachtestwithinadomain(eTable2in Supplement2 ).
Depressivesymptomseveritywasassessedusingcriterionstandardscales,the17-item
HamiltonRatingScaleforDepression(HRSD-17)withmaskedclinicianratingsand16-itemQuickInventoryofDepressiveSymptomatology–Self-Report(QIDS-SR-16)
24forpatientreports.Function
wasassessedusingtheSocialandOccupationalFunctioningAssessmentScale(SOFAS)25onascale
of0to100.
Functional Neuroimaging
Theimagingsubsampleunderwentfunctionalmagneticresonanceimagingusing3.0TeslaSignaHDx(GEHealthcare)withan8-channelheadcoilduringanestablishedcognitiveGo/No-Gotask,
12,26
engaginganequivalentdomainofcognitivecontrolasthecognitivebattery(eMethodsinSupplement2 ).Blood-oxygen-level–dependentcontrastfunctionalimageswereacquiredwithecho-
planarT2-weightedimaging(repetitiontime,2500ms;timetoecho,27.5ms;matrix,64 × 64;fieldofview,24cm;flipangle,90degrees;40slices,3.5mm–slicethickness,123volumes).Thecognitivetaskrobustlyengagesthedorsolateralprefrontal(dLPFC)anddorsalanteriorcingulate(dACC)regionsthatdefinethecognitivecontrolcircuit.
27DLPFCanddACCactivation,andfunctional
connectivitybetweenthem,wasquantifiedforeachpatientusingourpriorestablishedmethod(PanLabImagingPipeline)andexpressedasastandarddeviationvaluerelativetoahealthyreferencegroup,
27equivalenttoourprocedureforcognitivetests.Ahigh-resolutionT1-weightedstructural
scanwasacquiredforregistrationoffunctionalimages.JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 3/13
Downloaded from jamanetwork.com by guest on 07/17/2024
Exploratory Measures
Weincluded3additionalmeasuresoffactorsthatmightbealternativeexplanationsforcognitive
impairment:bodymassindex(BMI;calculatedasweightinkilogramsdividedbyheightinmeterssquared),anxietyassessedusingtheDepressionAnxietyStressScale-42(DASS-42)anxietysubscale,
28andbrainvolumequantifiedfromthestructuralscanusingvoxel-wisebrain
morphometryfor120regionsdefinedbytheAutomatedAnatomicalAtlas,anestablishedprocedureforiSPOT-D.
15
Responsewasdefinedasanimprovementofatleast50%ontheHRSD-17orQIDS-SR-16.We
definedsymptomremissionasanHRSD-17scoreof7orbeloworaQIDS-SR-16scoreof5orbelow.
Statistical Analysis
AnalyseswereundertakeninSPSSversion28(IBMCorp).Weimputedmissingvaluesthatwerelessthan5%ofthesample.Hypothesistestswere2-tailedexceptforχ
2testsexaminingsecondary
treatmenttypedifferences.Anominalα = .05wasusedforsignificanceforalltestsexceptsymptoms,forwhichweusedtheBenjamini-Hochbergmethod
29withfalsediscoveryrate(FDR)of
α = .05.Thismethodadjuststhe Pvaluesoftheindividualtests,consideringthenumberoftests
conductedandtheexpectedproportionoffalsepositives.WecalculatedeffectsizesasCohen d.
Deriving the Cognitive Biotype
Data-drivenclusteringwasusedtoidentifyacognitivebiotypebasedonimpairedcognitiveperformance.Expandingonapriorpreliminaryapproach,
30the9cognitivecompositescoreswere
enteredintoak-meansclusteringalgorithm,generating1through10clustersolutions.Theoptimalsolutionwasselectedbyconvergenceacrossmultiplecriteria:(1)screeplotelbowmethodusingsumofsquaredEuclideandistances,(2)silhouettemetric,and(3)clustersdifferonamaximumnumberofinputs.Wevalidatedtheclustersolutionforclinicalandmechanisticmeaningusingsymptom,functional,neuralcircuit,andtreatmentoutcomemeasuresnotusedasinputstogeneratetheclusters.
Depressive Symptoms, Functional Capacity, Neural Circuit Function, and Other Considerations
Cognitivebiotypes(positiveandnegative)werecomparedonoverallpretreatmentdepressivesymptomseverity,individualdepressivesymptoms,functionalcapacity,neuralcircuitfunction,andexploratoryBMI,anxiety,andbrainvolumemetricsusingindependentsample ttestswherethe
independentvariablewasthecognitivebiotypeandthedependentvariableisthedepressivesymptomseverity.Wealsocomparedclustersonindividualsymptomsusingindependentsample t
testscorrectedformultipletestingtodeterminewhetherthecognitivebiotypeisspecificallyassociatedwithparticulardepressivesymptoms.
Treatment Outcomes
χ
2testswereusedtocompareclustersonbinaryresponseandremissionwithantidepressant
treatmentandtypeoftreatmentat8weeks.Clusterswerecomparedonchangeinfunctionandcognitivemeasuresusingmixedmodelanalysisofvariance.
Treatment Outcomes as a Function of Cognitive Impairment
Tofurtherassessclinicalmeaningfulnessofthecognitivebiotype,weundertookmediationanalysestotestwhethersymptomandfunctionalimprovementfollowing8weeksoftreatmentrelyonimprovementincognitionat8weeks.MediationmodelswereimplementedusingthePreacher-Hayesbootstrappingmethodforestimatingasimplemediationmodelwithabinarypredictor X,a
continuousmediator M,andoutcomevariable Y.PROCESSMacrowasusedtoimplementthe
Preacher-HayesmethodinSPSS
31(with Xbeingcognitivebiotype; M,changeinexecutivefunction
orresponseinhibition; Y,changeinHRSD-17symptomratingorSOFAS;confidenceintervalbasedon
5000bootstrappedsamples)(eMethodsin Supplement2 ).Wenotethat,whiletemporalJAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 4/13
Downloaded from jamanetwork.com by guest on 07/17/2024
precedenceisidealinmediationmodels,themethodweuseddoesnotrequirethistobethecase.
Age,baselineHRSD-17,andfamilyhistoryofMDDwereusedascovariatesinthemediationmodels.
Results
Demographic Information
The1008MDDpatientswere18to65yearsold(mean[SD]age,37.8[12.6]years)and57%female(167[17%]Black,83[8%]Hispanic,625[62%]White).The96patientswhoparticipatedintheimagingsubstudywere47%femaleandhadameanageof34.5(13.5)years(eTable1inSupplement2 ).
Deriving a Cognitive Biotype
Screeplotandthesilhouettemetricindicateda2-clustersolutionwasoptimal(eResults,eFigure2in
Supplement2 ).The2-clustersolutiondifferedacrossallcognitivetestscores(all P< .001),thus
meetingourthirdcriterion.Theclustercharacterizedbymarkedimpairmentonallcognitivemeasureswaspresentin27%ofindividuals.Impairmentsweremostpronouncedforgoal-directedexecutivefunctionandresponseinhibitiondomains( Figure 1)relevanttotheresearchdomain
criteriacognitivecontrolconstruct(eTable2in Supplement2 ).Thesecondclusterwasanintact
cognitivesubgroupcharacterizedbyperformancewellwithinthehealthyrange(Figure1).Hereafter,werefertothesesubgroupsascognitivebiotypepositiveandcognitivebiotypenegativebasedontherationalethattheneurocognitivetestsaretappingintobiologicallybasedfunction.
Baseline Symptom Profiles and Neural Function
HRSD-17depressivesymptomseveritywassignificantlygreaterforthecognitivebiotypepositivethanthenegativesubgroup(meandifference,0.73; d= 0.18;95%CI,0.04to0.32; P= .01),yetthis
differencerepresentedlessthan1symptompoint.Clustersdidnotdifferonoverallself-reportedseverityontheQIDS-SR-16.Regardingindividualsymptoms,thecognitivebiotypepositivesubgroupwasdistinguishedbysimilarprofilesonboththeHRSD-17andQIDS-SR-16,includingslowerinformationprocessingandeffortfulthinkingorpsychomotorretardation(HRSD-17item8,QIDS-SR-16item15),morewakingduringthenight(HRSD-17item5),awakingearly(HRSD-17item6,QIDS-SR-16item3),andsleepingtoolittle(QIDS-SR-16item4)butsignificantlylessself-blame(QIDS-SR-16item11)( Figure 2A).
Thecognitivebiotypepositivesubgrouphadsignificantlygreaterfunctionalimpairment
pretreatmentcomparedwiththenegativesubgroup( d= −0.25;95%CI,−0.39to−0.11; P< .001)as
measuredbytheSOFAS( Figure 3).Cognitivetask-evokedneuralactivationwassignificantlyreduced
Figure 1. Baseline Cognitive Performance for Composite Measures in 2-Cluster Solution
0.5
–0.50
–1.0
–1.5
–2.0
–2.5Performance score, standardized mean (SE)
Cognitive biotypePositive NegativeDomain
Executive function
Response inhibition
Verbal memory
Sustained attention
Cognitive flexibility
Decision speed
Information
processing speed
Working memory
Psychomotor functionStandardizedmeanperformanceforbaselinecognitive
compositescoresacross9domainsforthe2-clustersolutionobtainedviak-meansclustering.Errorbarsrepresentthestandarderrorofthemean.Wehavedesignatedthe2clusterscognitivebiotypepositiveandcognitivebiotypenegative.JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 5/13
Downloaded from jamanetwork.com by guest on 07/17/2024
forthecognitivebiotypepositivesubgroupcomparedwiththenegativesubgroupinrightdLPFC
(d= −0.78;95%CI,−1.28to−0.27; P=.003)anddACC( d= −0.52;95%CI,−1.02to−0.02; P= .04)
regionsofthecognitivecontrolcircuit( Figure 4).Wedidnotfindanymeaningfuldifferences
betweenclustersinanxietyseverity,BMI,orstructuralbrainvolume(eResultsin Supplement2 ).
Cognitive Biotype and Treatment Outcomes at 8 Weeks
Thecognitivebiotypepositivesubgroupwasdistinguishedbysignificantlylowerratesofresponse
andremissiontoantidepressants(HRSD-17response,103of188[54.8%]vs340of524[64.9%];P= .02;HRSD-17remission,73of188[3 8.8%]vs250of524[47.7%]; P= .04).Thisbiotypealsohad
significantlylowerresponseandremissionratesforsertralineinparticular(HRSD-17response,31of64[48.4%]vs132of182[72.5%]; P< .001;HRSD-17remission,23of64[35.9%]vs91of182
[50.0%]; P= .04).Subgroupsdidnotdifferinprofilesofindividualsymptomimprovementwithin
responseandremissioncategories.Regardingfunctionalimpairmentposttreatment,therewasno
Figure 2. Baseline Individual Depression Scale Items Across Cognitive Biotypes
2.5
2.0
0.51.01.5
0Score, mean (SE)
Feeling slowed down (Q15)c
Concentration and
decision making (Q10)
Falling asleep (Q1)
Waking up too early (Q3)c
Increased appetite (Q7)
Decreased weight (Q8)
Energy level (Q14)
Feeling sad (Q5)View of myself (Q11)c
Sleep during the night (Q2)c
Sleeping too much (Q4)b
Decreased appetite (Q6)
Increased weight (Q9)
Feeling restless (Q16)
Thoughts of death
or suicide (Q12)
General interest (Q13)QIDSB
Depression item3
2
1
0Score, mean (SE)
Psychomotor
retardation (H8)a
Insight (H17)
Middle insomnia (H5)b
Loss of weight (H16)
Guilt (H2)
Suicide (H3)
Anxiety psychic (H10)
Somatic symptoms
GI (H12)Early insomnia (H4)
Late insomnia (H6)c
Agitation (H9)
Depressed mood (H1)
Work and activities (H7)
Anxiety somatic (H11)
Somatic symptoms
general (H13)
Genital symptoms (H14)
Hypochondriasis (H15)HDRS-17A
Depression itemPositiveCognitive biotype
Negative
Differencebetweencognitivebiotypesonindividual
itemsofthe17-itemHamiltonRatingScaleforDepression(HDRS-17)andthe16-itemQuickInventoryofDepressiveSymptoms–SelfReport(QIDS).Significantitemsgroupedaccordingtosymptomdomainwereasfollows:H8( d= .23;95%CI,0.09to
0.37; Pforfalsediscovery =.009),Q15( d=. 2 6 ;9 5 %
CI,0.12to0.41; Pforfalsediscovery < .001),H5
(d= .20;95%CI,0.06to0.34; Pforfalse
discovery = .03),Q2( d= .29;95%CI,0.15to0.44; P
forfalsediscovery <.001),H6( d= .33;95%CI,0.19to
0.47; Pforfalsediscovery <.001),Q3( d=. 2 6 ;9 5 %
CI,0.12to0.40; Pforfalsediscovery <.001),Q4
(d= −.22;95%CI,−0.36to−0.07; Pforfalse
discovery = .01),andQ11( d= −.26;95%CI,−0.40to
−0.12; Pforfalsediscovery <.001).Errorbars
representthestandarderrorofthemean.GIindicatesgastrointestinal.
aP< .05.
bP< .01.
cP< .001.JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 6/13
Downloaded from jamanetwork.com by guest on 07/17/2024
interactionofthecognitivebiotypewithpretreatmentvsposttreatmentchangeinpsychosocial
functionasmeasuredbySOFAS.Cognitiveimpairmentspersistedposttreatmentinthecognitivebiotypepositivesubgroup,remainingatleast0.2standarddeviationsbelowthehealthymean,whereasperformanceimprovedduringthetreatmentperiodforthebiotypenegativesubgroupfurtherintothehealthyrangeinsomedomains,includingexecutivefunction(eFigure3inSupplement2 ).
Cognitive Impairment and Overall Symptom Response Following 8 Weeks
of Treatment
Mediationmodelsfocusedonexecutivefunctionandresponseinhibitionbecausetheyweremost
significantlyimpairedinthecognitivebiotypepositivesubgroup.Lackofchangeincognitivecontrolperformancewasasignificantmediatoroftheassociationbetweenpretreatmentcognitivebiotypeandlackofoverallsymptomrelieffollowingtreatment(indirecteffect a×b=− 0 . 2 4 ; bootstrapped
95%CI,−0.49to−0.02)( Figure 5A),butthereversewasnottrue.Thismediatorsignificantly
contributedtothetotaleffectmodel( t=− 2 . 0 9 ;β=− 1 . 1 7 ; P= .03)buttherewasnodirecteffect
Figure 3. Baseline Social and Occupational Functioning Across Cognitive Biotypes
60
55
4050
45
35SOFAS score, mean (SE)
Cognitive biotypea
Positive NegativeDifferencebetweencognitivebiotypesontheSocial
andOccupationalFunctioningAssessmentScale(SOFAS).Errorbarsrepresentthestandarderrorofthemean.
aP< .001.
Figure 4. Illustration of the Cognitive Control Circuit and Baseline Task-Evoked Activation in the Cognitive
Control Circuit Across Cognitive Biotypes
0.2
0
–0.2
–0.4
–0.6
–0.8
–1.0Activity, standardized mean (SE)
Brain regiona
dLPFC rightNS
dLPFC leftb
dACCPositive NegativeCognitive biotype
Go/No-Go task differenceB Key brain regionsA
dACC
dLPFC
 dLPFC
Errorbarsrepresentthestandarderrorofthemean.
dACCindicatesdorsalanteriorcingulatecortex;dLPFC,dorsolateralprefrontalcortex.
aP< .05.
bP< .01.JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 7/13
Downloaded from jamanetwork.com by guest on 07/17/2024
betweencognitivebiotypeandsymptomrelief( t= −1.63; P= .10).SeeeResultsin Supplement2 for
furtherdiscussionofmediationresults.
Discussion
Overall,ourmultimodalfindingssuggestthepresenceofacognitivebiotypeofdepressionthatrepresentsaboutaquarterofalldepressedpatientsandischaracterizedbyprominentimpairmentsin2domainsofcognitivecontrol(executivefunctionandresponseinhibition).Thiscognitivebiotypehasgreaterseverityinbaselinesymptomsofslowedinformationprocessingandinsomnia,poorpsychosocialfunction,reducedneuralfunctionofthebrain’scognitivecontrolcircuit,andpooreroutcomesfollowingfirst-lineantidepressanttreatment.Theextentofcognitivecontrolimpairmentalsomediatedtheextentof(orlackof)symptomandpsychosocialimprovementposttreatment.
Theidentificationofadistinctivecognitivebiotypeidentifiedbyamachinelearningclustering
algorithmhighlightsthevalueofdisentanglingtheheterogeneityofdepressiontounderstandthesourceofmeancognitiveimpairmentswithinthediagnosisofdepressionasabroadcategory.Thisbiotypemightbeamajorcontributortopriormeanobservationsofimpairedexecutivefunctionandresponseinhibitionwithinthedepressiondiagnosiscomparedwithhealthypeers.
32
Addingfurthertothevalueofdisentanglingheterogeneityindepression,thecognitivebiotype
identifiedinthisstudywasdistinguishedmorebyaspecificprofileofindividualsymptomsthanbyoveralldepressionseverity.Thisbiotypewascharacterizedbyslowedthinking(whichcouldbeanticipatedgiventhecognitivefocusofthisbiotype)aswellassleepproblems,andalignswithprior
Figure 5. Mediation Models for Response Inhibition and Executive Function Using Depressive Symptoms
and Functional Capacity as Outcomes
M. Response inhibition
X. Cognitive biotype Y. Depressive symptomsResponse inhibition and depressive symptomsA
Direct effect  = –0.930.56a –0.43b
Mediation of X on Y via M  = –0.24; 95% CI, –0.49 to –0.02
Total effect  = –1.17
M. Executive function
X. Cognitive biotype Y. Functional capacityExecutive function and depressive symptomsB
Direct effect  = 0.300.86a 1.37b
Mediation of X on Y via M  = 1.18; 95% CI, 0.55 to 1.95
Total effect  = 1.48
M. Response inhibition
X. Cognitive biotype Y. Functional capacityResponse inhibition and functional capacityC
Direct effect  = 0.780.55a 1.26a
Mediation of X on Y via M  = 0.70; 95% CI, 0.28 to 1.23
Total effect  = 1.48Depressivesymptomsweremeasuredusingthe
17-itemHamiltonRatingScaleforDepressionandfunctionalcapacityusingtheSocialandOccupationalFunctioningAssessmentScale.Coefficientsareunstandardized.Grayarrowsindicatepositiveassociations;orangearrows,negativeassociations.
aP< .001.
bP< .05.
cP< .10.JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 8/13
Downloaded from jamanetwork.com by guest on 07/17/2024
observedassociationsbetweendepression,executivefunction,andsleep.33Onpsychosocialratings,
thecognitivebiotypewasfurtherdistinguishedbypoorsocialandoccupationalfunction,addingspecificitytoevidencethatcognitiveimpairmentisamajorcontributortodisabilityindepression.
1
Ourobservationthatthecognitivesubtypewascharacterizedbyreducedactivationofthe
dLPFCanddACCwithinthecognitivecontrolcircuitsuggestsadistinctneuralmechanisticprocessunderlyingthisbiotype.Reducedactivationintheseprefrontalregionsalignswiththepriorproposedcognitivecontrolbiotypebasedonasynthesisofneuroimagingfindings
13andtheroleofthese
regionsincognitivecontrolperformance.Auniquefeatureofourdatasetwastheopportunitytoassesstheimpactofthespecificcognitivebiotypeonoutcomesfollowingtreatment.Thiscognitivebiotypehadlowratesofbothsymptomresponseandremissionfollowingantidepressants,particularlyfortreatmentwithsertraline.Posttreatment,thecognitivebiotypealsoshowedcontinuedcognitivecontrolimpairmentandlessimprovementinpsychosocialfunctionregardlessofsymptomchange.Inmediationmodels,wedemonstratedthatlessimprovementincognitivecontrolspecificallymediatedtherelationshipbetweenpretreatmentbiotypeandextentofposttreatmentrelieffromdepressivesymptoms.Similarly,lesschangeincognitivecontrolperformancemediatedlessimprovementinpsychosocialfunctionfollowingtreatment.Thesemediationfindingssuggestthatforasubstantialminorityofdepressedpatientsitisnecessarytoimprovecognitioninordertoimproveoveralldepressedmoodandfunction.Thefindingschallengetheprevailingassumptionthatcognitiveimpairmentsresolveasasecondaryeffectofimprovingoverallseverity.
Ourfindingsaddtothegrowingevidencethattreatmentsspecificallytargetingcognitive
impairmentanditsmechanismsindepressionareurgentlyneeded.
34,35Only1FDA-approved
antidepressant—vortioxetine—hasshownpromiseforimprovingcognition36;however,the
mechanismsunderlyingvortioxetine’scognitive-enhancingeffectsareunknown.Futurestudiesshouldutilizebiomarkerdesignstoevaluatewhetheroutcomesforthecognitivebiotypeareenhancedwhenmatchedtoatreatmentwithmechanismstargetingcognitivecontrolcircuitryandbehaviors.
Limitations
Ourfindingsmustbeconsideredinthecontextofseveralpotentiallimitations.First,althoughweruleoutdisordersandotherfactorsthatcouldaffectcognitiveimpairment,itremainspossiblethatotherasyetunidentifiedbehavioralorneurobiologicalfactorscontributetothecognitivebiotype.Second,althoughoursamplewasrepresentativeofmultipleracialandethnicbackgroundsandclinicalsettings,thefindingsmustbeevaluatedforgeneralizability.Third,thepragmaticbiomarkerdesignofthetrialfocusedon3commonlyprescribedantidepressantsandtherelevanceofourapproachtootherantidepressantsandtreatmentmodalitiesrequiresinvestigation.Finally,withinthemediationmodels,weacknowledgesomeoverlapinmeasuresusedtoallocate Xandassesschangein M,but
nottotheextentofaconfounder.Futurestudiesarewarrantedtoteststrongercausalinferencesinadesignoptimizedbyexperimentalmanipulationofcognitivebiotype( X)andthroughestablishingan
explicittemporalprecedencebetween MandY.Ourputativemediator,cognitivechange,issuitable
tosuchdesigns,asitisamenabletobothmeasurementandmanipulation.Likewise,wealsoacknowledgethereissomecircularityinusingtheGo/No-Gotasktobothgeneratethecognitivebiotypecategories(positiveandnegative)andlinkthebiotypestoGo/No-Go–evokedbrainresponse.
Conclusions
Toourknowledge,thisisthefirststudytocombinebiologicalandnonbiologicalmeasurestoverifyadistinct,clinicallyactionablecognitivebiotypeofdepression.IftheprevalenceofcognitivedeficitsinoursampleisgeneralizedtotheUSpopulation,thenapproximately5.7millionindividualswithdepressionhavecognitiveimpairments(27%of21million).IncorporatingneuralcircuitmeasuresenablesadeeperunderstandingoftheneurobiologicalmechanismsthatunderpinthesecognitiveJAMA Network Open | Psychiatry
CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 9/13
Downloaded from jamanetwork.com by guest on 07/17/2024
impairmentsandhasimplicationsforprecisiontreatmentapproachesinfuturestudiesandin
practice.Biomarkertrialstargetingthecognitivebiotypewithmoreselectivetreatmentstrategiesareurgentlyneeded.
ARTICLE INFORMATION
Accepted for Publication: April27,2023.
Published: June15,2023.doi: 10.1001/jamanetworkopen.2023.18411
Correction: ThisarticlewascorrectedonJuly12,2023,tofixthetitleandanerrorappearingintheAbstract
andResults.
Open Access: Thisisanopenaccessarticledistributedunderthetermsofthe CC-BYLicense .©2023HackLM
etal. JAMA Network Open .
Corresponding Author: LeanneM.Williams,PhD,DepartmentofPsychiatryandBehavioralSciences,Stanford
University,Stanford,CA94305( leawilliams@stanford.edu ).
Author Affiliations: DepartmentofPsychiatryandBehavioralSciences,StanfordUniversity,Stanford,California
(Hack,Tozzi,Zenteno,Olmsted,Hilton,Jubeir,Schatzberg,Yesavage,O’Hara,Williams);Sierra-PacificMentalIllnessResearch,Education,andClinicalCenter(MIRECC)VeteransAffairsPaloAltoHealthCareSystem,PaloAlto,California(Hack,Olmsted,Yesavage,O’Hara,Williams);BrainDynamicCentre,WestmeadInstituteforMedicalResearch,TheUniversityofSydney,Westmead,NewSouthWales,Australia(Korgaonkar).
Author Contributions: DrWilliamshadfullaccesstoallofthedatainthestudyandtakesresponsibilityforthe
integrityofthedataandtheaccuracyofthedataanalysis.
Concept and design: Schatzberg,O’Hara,Williams.
Acquisition, analysis, or interpretation of data: Hack,Tozzi,Zenteno,Olmsted,Hilton,Jubeir,Korgaonkar,
Schatzberg,Yesavage,Williams.
Drafting of the manuscript: Hack,Zenteno,Hilton,Jubeir,Schatzberg,Williams.
Critical revision of the manuscript for important intellectual content: Tozzi,Olmsted,Hilton,Jubeir,Korgaonkar,
Yesavage,O’Hara,Williams.
Statistical analysis: Hack,Olmsted,Schatzberg,Williams.
Obtained funding: Williams.
Administrative, technical, or material support: Olmsted,Hilton,Jubeir,Korgaonkar,Yesavage,O’Hara.
Supervision: Tozzi,Hilton,Jubeir,Williams.
Conflict of Interest Disclosures: DrHackreportedpersonalfeesfromRocheAdvisoryBoardoutsidethe
submittedwork.DrKorgaonkarreportedgrantsfromTakedaPharmaceuticalLtdoutsidethesubmittedwork.DrSchatzbergreportedpersonalfeesfromANeuroTech,personalfeesfromNeuroWell,personalfeesfromSAGE,nonfinancialsupportfromALTO,nonfinancialsupportfromMagnusHealth,personalfeesfromDelpor,andpersonalfeesfromDouglasoutsidethesubmittedwork.DrYesavagereportedgrantsfromStanfordUniversity,NationalInstitutesofHealth,USVeteransAdministrationduringtheconductofthestudy.DrWilliamsreportedreceivinggrantfundingfromNationalInstitutesofMentalHealthfordataacquisitionandresearchpersonnelduringtheconductofthestudy;shereportedreceivingpersonalfeesforadvisoryboardfromOneMindPsyberguideandLaureateInstituteforBrainResearchoutsidethesubmittedwork;shereportedserviceontheadvisoryboardforRocheoutsidethesubmittedwork;inaddition,DrWilliamsreportedholdingapatent(No.16921388)issuedtoEtCereInc.Nootherdisclosureswerereported.
Funding/Support: TheInternationalStudytoPredictOptimizedTreatmentinDepression(iSPOT-D)issponsored
byBrainResourceCompanyOperationsPtyLtd.ThisworkwasalsosupportedbyStanford’sClinicalandTranslationalScienceAwardProgramoverseenbytheNationalCenterforAdvancingTranslationalSciencesattheNationalInstitutesofHealth(UL1TR003142-01,O’Hara).
Role of the Funder/Sponsor: Thefundershadnoroleinthedesignandconductofthestudy;collection,
management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;andthedecisiontosubmitthemanuscriptforpublication.
Data Sharing Statement: SeeSupplement3 .
Additional Contributions: Theauthorswouldliketoextendtheirappreciationtothepatientsinthestudy,who
werecompensatedfortheirparticipation.WewouldalsoliketoacknowledgetheeditorialsupportofJonKilner,MS,MA,whoreceivedcompensationforhisrole.WeacknowledgetheiSPOT-DInvestigatorsGroup,andtheJAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 10/13
Downloaded from jamanetwork.com by guest on 07/17/2024
contributionsofprincipalinvestigatorsateachsite: academic principal investigator ,LeanneM.Williams,PhD,
StanfordUniversity; sponsor investigator ,EvianGordon,PhD; iSPOT-D investigators group ,MartijnArns,Nijmegen;
XiaoLeiYuBaran,CornellUniversity;CharlesDebattista,StanfordUniversity;StevenBruce,UniversityofMissouri,StLouis;C.RichardClark,FlindersUniversity;BarbaraA.Cohen,CenterforHealingtheHumanSpirit;RogerdeBeus,SkylandBehavioralHealthAssociates;KamranFallahpour,BrainResourceCenter;PaulFitzgerald,MonashUniversityandAlfredHospital;AnthonyW.F.Harris,UniversityofSydney–WestmeadClinicalSchool;LawrenceHirshberg,NeurodevelopmentalCenter;JayashriKulkarni,AlfredHospitalandDelmontHospital;HarbansMultani,ShantiClinicalTrials;BruceRussell,UniversityofAuckland;RaduSaveanu,MiamiUniversity;ConStough,SwinburneUniversity;SubhdeepVirk,OhioStateUniversity;ElizabethWallis,BrainHealthLab,MedicalUniversityofSouthCarolina.ClaireDay,PhD,wastheglobaltrialmanagerforiSPOT-Dfrom2009to2015.
REFERENCES
1. LamRW,KennedySH,MclntyreRS,KhullarA.Cognitivedysfunctioninmajordepressivedisorder:effectson
psychosocialfunctioningandimplicationsfortreatment. Can J Psychiatry .2014;59(12):649-654.doi: 10.1177/
070674371405901206
2. InselT,CuthbertB,GarveyM,etal.Researchdomaincriteria(RDoC):towardanewclassificationframeworkfor
researchonmentaldisorders. Am J Psychiatry .2010;167(7):748-751.doi: 10.1176/appi.ajp.2010.09091379
3. AmericanPsychiatricAssociation. Diagnostic and Statistical Manual of Mental Disorders. 5thed.American
PsychiatricAssociation;2013.
4. SoczynskaJK,RavindranLN,StyraR,etal.TheeffectofbupropionXLandescitalopramonmemoryand
functionaloutcomesinadultswithmajordepressivedisorder:resultsfromarandomizedcontrolledtrial.Psychiatry Res .2014;220(1-2):245-250.doi: 10.1016/j.psychres.2014.06.053
5. VietaE,SluthLB,OlsenCK.Theeffectsofvortioxetineoncognitivedysfunctioninpatientswithinadequate
responsetocurrentantidepressantsinmajordepressivedisorder:ashort-term,randomized,double-blind,exploratorystudyversusescitalopram. J Affect Disord .2018;227:803-809.doi: 10.1016/j.jad.2017.11.053
6. Schüssler-FiorenzaRoseSM,BottNT,HeinemeyerEE,etal.Depression,healthcomorbidities,cognitive
symptomsandtheirfunctionalimpact:notjustageriatricproblem. J Psychiatr Res .2021;139:185-192.doi: 10.1016/
j.jpsychires.2021.05.013
7. PeriniG,CottaRamusinoM,SinforianiE,BerniniS,PetrachiR,CostaA.Cognitiveimpairmentindepression:
recentadvancesandnoveltreatments. Neuropsychiatr Dis Treat .2019;15:1249-1258.doi: 10.2147/NDT.S199746
8. ZuckermanH,PanZ,ParkC,etal.Recognitionandtreatmentofcognitivedysfunctioninmajordepressive
disorder. Front Psychiatry .2018;9:655.doi: 10.3389/fpsyt.2018.00655
9. ShilyanskyC,WilliamsLM,GyurakA,HarrisA,UsherwoodT,EtkinA.Effectofantidepressanttreatmenton
cognitiveimpairmentsassociatedwithdepression:arandomisedlongitudinalstudy. Lancet Psychiatry .2016;3(5):
425-435.doi: 10.1016/S2215-0366(16)00012-2
10. EtkinA,PatenaudeB,SongYJ,etal.Acognitive-emotionalbiomarkerforpredictingremissionwith
antidepressantmedications:areportfromtheiSPOT-Dtrial. Neuropsychopharmacology .2015;40(6):1332-1342.
doi:10.1038/npp.2014.333
11. GyurakA,PatenaudeB,KorgaonkarMS,GrieveSM,WilliamsLM,EtkinA.Frontoparietalactivationduring
responseinhibitionpredictsremissiontoantidepressantsinpatientswithmajordepression. Biol Psychiatry .2016;
79(4):274-281.doi: 10.1016/j.biopsych.2015.02.037
12. TozziL,Goldstein-PiekarskiAN,KorgaonkarMS,WilliamsLM.Connectivityofthecognitivecontrolnetwork
duringresponseinhibitionasapredictiveandresponsebiomarkerinmajordepression:evidencefromarandomizedclinicaltrial. Biol Psychiatry .2020;87(5):462-472.doi: 10.1016/j.biopsych.2019.08.005
13. WilliamsLM.Precisionpsychiatry:aneuralcircuittaxonomyfordepressionandanxiety. Lancet Psychiatry .
2016;3(5):472-480.doi: 10.1016/S2215-0366(15)00579-9
14. WilliamsLM,RushAJ,KoslowSH,etal.InternationalStudytoPredictOptimizedTreatmentforDepression
(iSPOT-D),arandomizedclinicaltrial:rationaleandprotocol. Trials.2011;12:4.doi: 10.1186/1745-6215-12-4
15. GrieveSM,KorgaonkarMS,EtkinA,etal.Brainimagingpredictorsandtheinternationalstudytopredict
optimizedtreatmentfordepression:studyprotocolforarandomizedcontrolledtrial. Trials
.2013;14:224.doi: 10.
1186/1745-6215-14-224
16. ClarkCR,PaulRH,WilliamsLM,etal.Standardizedassessmentofcognitivefunctioningduringdevelopment
andagingusinganautomatedtouchscreenbattery. Arch Clin Neuropsychol .2006;21(5):449-467.doi: 10.1016/j.
acn.2006.06.005JAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 11/13
Downloaded from jamanetwork.com by guest on 07/17/2024
17. WilliamsLM,SimmsE,ClarkCR,PaulRH,RoweD,GordonE.Thetest-retestreliabilityofastandardized
neurocognitiveandneurophysiologicaltestbattery:“neuromarker”. Int J Neurosci .2005;115(12):1605-1630.doi:
10.1080/00207450590958475
18. PaulRH,LawrenceJ,WilliamsLM,RichardCC,CooperN,GordonE.Preliminaryvalidityof“integneuro”:anew
computerizedbatteryofneurocognitivetests. Int J Neurosci .2005;115(11):1549-1567.doi: 10.1080/
00207450590957890
19. RoweDL,CooperNJ,LiddellBJ,ClarkCR,GordonE,WilliamsLM.Brainstructureandfunctioncorrelatesof
generalandsocialcognition. J Integr Neurosci .2007;6(1):35-74.doi: 10.1142/S021963520700143X
20. WilliamsLM,HermensDF,TheinT,etal.Usingbrain-basedcognitivemeasurestosupportclinicaldecisionsin
ADHD. Pediatr Neurol .2010;42(2):118-126.doi: 10.1016/j.pediatrneurol.2009.08.010
21. BraundTA,TillmanG,PalmerDM,HarrisAWF.Verbalmemorypredictstreatmentoutcomeinsyndromal
anxiousdepression:aniSPOT-Dreport. J Affect Disord .2020;260:245-253.doi: 10.1016/j.jad.2019.09.028
22. WilliamsLM,WhitfordTJ,FlynnG,etal.Generalandsocialcognitioninfirstepisodeschizophrenia:
identificationofseparablefactorsandpredictionoffunctionaloutcomeusingtheIntegNeurotestbattery.Schizophr Res .2008;99(1-3):182-191.doi: 10.1016/j.schres.2007.10.019
23. HatchA,MaddenS,KohnMR,etal.Infirstpresentationadolescentanorexianervosa,docognitivemarkersof
underweightstatuschangewithweightgainfollowingarefeedingintervention? Int J Eat Disord .2010;43(4):
295-306.doi: 10.1002/eat.20695
24. RushAJ,TrivediMH,IbrahimHM,etal.The16-ItemQuickInventoryofDepressiveSymptomatology(QIDS),
clinicianrating(QIDS-C),andself-report(QIDS-SR):apsychometricevaluationinpatientswithchronicmajordepression. Biol Psychiatry .2003;54(5):573-583 .
25. GoldmanHH,SkodolAE,LaveTR.RevisingaxisVforDSM-IV:areviewofmeasuresofsocialfunctioning. Am J
Psychiatry .1992;149(9):1148-1156.doi: 10.1176/ajp.149.9.1148
26. KorgaonkarMS,GrieveSM,EtkinA,KoslowSH,WilliamsLM.UsingstandardizedfMRIprotocolstoidentify
patternsofprefrontalcircuitdysregulationthatarecommonandspecifictocognitiveandemotionaltasksinmajordepressivedisorder:firstwaveresultsfromtheiSPOT-Dstudy. Neuropsychopharmacology .2013;38(5):863-871.
doi:10.1038/npp.2012.252
27. Goldstein-PiekarskiAN,BallTM,SamaraZ,etal.Mappingneuralcircuitbiotypestosymptomsandbehavioral
dimensionsofdepressionandanxiety. Biol Psychiatry .2022;91(6):561-571.doi: 10.1016/j.biopsych.2021.06.024
28. LovibondSH,LovibondPF. Manual for the Depression Anxiety Stress Scales .PsychologyFoundationof
Australia;1995.
29. BenjaminiY,HochbergY.Controllingthefalsediscoveryrate:apracticalandpowerfulapproachtomultiple
testing. J R Stat Soc B .1995;57(1):289-300.
30. SchatzbergAF,DeBattistaC,LazzeroniLC,EtkinA,MurphyGMJr,WilliamsLM.ABCB1geneticeffectson
antidepressantoutcomes:areportfromtheiSPOT-DTrial. Am J Psychiatry .2015;172(8):751-759.doi: 10.1176/appi.
ajp.2015.14050680
31. HayesAF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based
Approach .GuilfordPress;2013.
32. CulpepperL,LamRW,McIntyreRS.Cognitiveimpairmentinpatientswithdepression:awareness,
assessment,andmanagement. J Clin Psychiatry .2017;78(9):1383-1394.doi: 10.4088/JCP.tk16043ah5c
33. WilckensKA,KlineCE,BowmanMA,etal.Doesobjectively-assessedsleepmoderatetheassociationbetween
historyofmajordepressivedisorderandtask-switching? J Affect Disord .2020;265:216-223.doi:
10.1016/j.jad.
2020.01.003
34. ElliottR,BakerSC,RogersRD,etal.Prefrontaldysfunctionindepressedpatientsperformingacomplex
planningtask:astudyusingpositronemissiontomography. Psychol Med .1997;27(4):931-942.doi: 10.1017/
S0033291797005187
35. PuS,SetoyamaS,NodaT.Associationbetweencognitivedeficitsandsuicidalideationinpatientswithmajor
depressivedisorder. Sci Rep.2017;7(1):11637.doi: 10.1038/s41598-017-12142-8
36. BennabiD,HaffenE,VanWaesV.Vortioxetineforcognitiveenhancementinmajordepression:fromanimal
modelstoclinicalresearch. Front Psychiatry .2019;10:771.doi: 10.3389/fpsyt.2019.00771
SUPPLEMENT 1.
Trial Protocol and Statistical Analysis PlanJAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 12/13
Downloaded from jamanetwork.com by guest on 07/17/2024
SUPPLEMENT 2.
eMethods. SupplementalMethods
eResults. SupplementalResults
eTable 1. DemographicandClinicalCharacteristicsofParticipantsatBaseline
eTable 2. NeurocognitiveDomains,Tests,andDescriptions
eFigure 1. CONSORTDiagram
eFigure 2. ScreePlotofthek-meansClusteringSolutionswithDifferentNumbersofClusters
eFigure 3. PosttreatmentCognitivePerformanceforCompositeMeasuresinCognitiveBiotypes
eReferences.
SUPPLEMENT 3.
Data Sharing StatementJAMA Network Open | Psychiatry CognitiveBiotypeofDepressionLinkingSymptoms,BehaviorMeasures,NeuralCircuits,andTreatmentOutcomes
JAMA Network Open. 2023;6(6):e2318411.doi:10.1001/jamanetworkopen.2023.18411 (Reprinted) June 15,2023 13/13
Downloaded from jamanetwork.com by guest on 07/17/2024